{
    "Trade/Device Name(s)": [
        "QuantStudio\u2122 Dx Real-Time PCR Instrument"
    ],
    "Submitter Information": "Life Technologies Corporation",
    "510(k) Number": "K123955",
    "Predicate Device Reference 510(k) Number(s)": [
        "K092705"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "OOI"
    ],
    "Summary Letter Date": "December 20, 2012",
    "Summary Letter Received Date": "December 21, 2012",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21CFR862.2570"
    ],
    "Regulation Name(s)": [
        "Instrumentation for clinical multiplex test systems"
    ],
    "Analyte Class(es)": [
        "microbiology",
        "genetic molecular"
    ],
    "Analyte(s)": [
        "Clostridium difficile nucleic acid sequences"
    ],
    "Specimen Type(s)": [
        "Human-derived specimens",
        "Fecal specimens"
    ],
    "Specimen Container(s)": [
        ""
    ],
    "Instrument(s)/Platform(s)": [
        "QuantStudio\u2122 Dx Real-Time PCR Instrument"
    ],
    "Method(s)/Technology(ies)": [
        "Real-time PCR",
        "Fluorescence-based PCR"
    ],
    "Methodologies": [
        "Nucleic acid amplification",
        "Qualitative and quantitative detection",
        "Molecular testing"
    ],
    "Submission Type(s)": [
        "Instrument",
        "System",
        "Software"
    ],
    "Document Summary": "FDA 510(k) summary for Life Technologies QuantStudio\u2122 Dx Real-Time PCR Instrument for qualitative and quantitative detection of nucleic acid sequences using fluorescence-based PCR",
    "Indications for Use Summary": "Intended to perform fluorescence-based PCR to detect FDA cleared and approved nucleic acid sequences in human-derived specimens; for in vitro diagnostic use by trained laboratory technologists with compatible nucleic acid reagent kits/tests.",
    "fda_folder": "Clinical Chemistry"
}